World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
105
Citations
43097
World Ranking
589
National Ranking
15

Medicine

D-Index
105
Citations
43222
World Ranking
6740
National Ranking
223

Adriano Lazzarin publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Adriano Lazzarin sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 898 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Adriano Lazzarin D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Adriano Lazzarin sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 105 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Adriano Lazzarin is affiliated with Vita-Salute San Raffaele University in Italy. Their scholarly work primarily spans the field of Medicine, with a distinct focus on Infectious Diseases, Virology, Emergency Medicine, Epidemiology, and Hepatology.

Their research topics include:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV-related health complications and treatments
  • Hepatitis C virus research
  • COVID-19 Clinical Research Studies
  • Pharmacological Effects and Toxicity Studies

Recent publications from Adriano Lazzarin reveal a focus on infectious disease management and COVID-19 clinical research. Selected recent papers include:

  • "Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors" (2020), published in Clinical Microbiology and Infection
  • "Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy" (2020), published in Clinical Immunology
  • "Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls" (2020), published in Clinical Infectious Diseases
  • "Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial" (2021), published in The Lancet HIV
  • "Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19" (2020), published in Scientific Reports

Frequent coauthors of Adriano Lazzarin include:

  • Antonella Castagna
  • Antonella d'Arminio Monforte
  • Andrea Antinori
  • Nicola Gianotti
  • Laura Galli

Adriano Lazzarin has contributed multiple publications to several prominent journals, notably:

  • Journal of Antimicrobial Chemotherapy
  • Open Forum Infectious Diseases
  • UNC Libraries
  • Clinical Infectious Diseases
  • AIDS

Best Publications

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

    Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

    Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

    Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  • Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

    Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

    Mark R. Nelson;Christine Katlama;Julio S. Montaner;David A. Cooper

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system

    P. Cinque;M. Brytting;B. Wahren;A. Linde

  • Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

    Kathleen Squires;Adriano Lazzarin;José M. Gatell;William G. Powderly

  • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama

  • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

    Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  • The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

    Giuseppe Pantaleo;James F. Demarest;Timothy Schacker;Mauro Vaccarezza

  • Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors.

    Marco Ripa;Laura Galli;Andrea Poli;Chiara Oltolini

  • A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection

    Sabine Kinloch De Loës;Bernard J. Hirschel;Bruno Hoen;David A. Cooper

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

    Unknown

Frequent Co-Authors

Antonella Castagna
Antonella Castagna Vita-Salute San Raffaele University
Giuseppe Tambussi
Giuseppe Tambussi Vita-Salute San Raffaele University
Paola Cinque
Paola Cinque Vita-Salute San Raffaele University
Massimo Galli
Massimo Galli University of Milan
Mauro Moroni
Mauro Moroni University of Milan
Guido Poli
Guido Poli Vita-Salute San Raffaele University
Massimo Clementi
Massimo Clementi Vita-Salute San Raffaele University
Antonella d'Arminio Monforte
Antonella d'Arminio Monforte University of Milan
Andrea Antinori
Andrea Antinori Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Cristina Mussini
Cristina Mussini University of Modena and Reggio Emilia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can broaden career opportunities within healthcare and research fields. Accelerated nursing programs, such as accelerated np programs, provide a fast track to becoming a Nurse Practitioner, combining clinical skills with immunology knowledge to treat patients effectively.

Individuals without a nursing background can still enter the field through online ABSN programs for non nurses, which allow direct entry into nursing with flexible, accessible coursework tailored for career changers. These programs can complement immunology studies with foundational healthcare training.

For those seeking less competitive entry points, options like the easiest accelerated nursing programs offer accessible pathways to earn a Bachelor of Science in Nursing quickly and efficiently while gaining exposure to immunological principles applicable in many clinical settings.

Additionally, starting with practical nursing credentials from LPN schools easy to get into can provide valuable hands-on experience. Licensed Practical Nurses often work closely with immunologists and researchers, gaining insights that can guide future advanced education.

Best Scientists Citing Adriano Lazzarin

Trending Scientists

Recently Published Articles